Project Grant R43AI186702
Award Date
7/8/24
Completion Date
6/30/26
Dollars Obligated
$299K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Northampton, MA 01060, USA
Similar Awards
This Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $991,832 to Astek Diagnostics Inc., a minority-owned small business, to develop a novel rapid antibiotic susceptibility testing (AST) platform. The project aims to deliver results in under one hour for various specimen types, including urine, cerebrospinal fluid, and wound effluent. This innovative platform is designed to quickly identify...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The goal is to create a microfluidic-enabled technology that can isolate small numbers of bacteria directly from whole blood, identify bacterial pathogens, and evaluate their antibiotic response within 75...
The National Science Foundation (NSF) awarded a $305,000 Project Grant under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) to Giant Biosystems Inc., a small disadvantaged business, to develop a rapid point-of-care antimicrobial susceptibility testing (AST) kit. The project aims to create a microfluidic platform that can provide actionable AST results within 6-9 hours, as opposed to the current 3-5 day turnaround. This will allow physicians to more quickly prescribe...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Salus Discovery LLC, a for-profit limited liability company. The grant will fund the development of Salus Discovery's FLOW DIRECT platform, a next-generation urine lateral flow assay (LFA) for tuberculosis (TB) diagnosis in point-of-care settings. The project aims to improve the accuracy, accessibility, and affordability of...
This federal Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $1,350,312 award is supporting the development of a rapid, phenotypic drug susceptibility testing system for tuberculosis (TB). The key products and services being delivered under this grant include: Developing and optimizing novel fluorescent trehalose probes (3HC-TRE and RMR-TRE) to specifically detect...
This Project Grant award of $305,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a transformative diagnostic platform by Resonantia Diagnostics, Inc. The platform aims to rapidly identify pathogens and determine their antimicrobial susceptibility within 60 minutes directly from patient samples. By enabling fast, evidence-based treatment decisions at the point of care, this innovation has the potential...
This $275,000 Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The project, led by Informuta, Inc., a for-profit organization based in New Orleans, LA, will establish the feasibility of leveraging mutational signatures found in bacterial DNA to predict antibiotic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $163,698 to Magic Lifescience, Inc. to develop a novel point-of-care (POC) molecular diagnostic assay for syphilis detection. The goal is to create a multiplexed genital ulcer disease (GUD) panel test that can rapidly and accurately diagnose syphilis, as well as other pathogens causing GUD, using giant magnetoresistive...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $238,500 to the University of California, San Diego (UCSD) to develop a novel electrochemical lateral flow assay (ELFA) that can accurately diagnose active tuberculosis (TB) from a single drop of blood or urine. The primary objectives are to: 1) Determine the operating characteristics of the ELFA using contrived...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Baebies, Inc., a Durham, North Carolina-based company that specializes in advanced medical diagnostic equipment and devices. The purpose of this grant is to develop a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs), reduce overtreatment, and prevent the emergence of...